AlexanderEPerlMD
Oncology • Philadelphia, PAHematologic Oncology
Assistant Professor, Medicine, Perelman School of Medicine
Dr. Perl is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3400 Spruce St
12-154 PCAM South Tower
Philadelphia, PA 19104Phone+1 215-662-4794- Is this information wrong?
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2001 - 2003
University of California (San Francisco)Residency, Internal Medicine, 1997 - 2000
Icahn School of Medicine at Mount SinaiClass of 1997
Certifications & Licensure
CA State Medical License 1999 - Present
PA State Medical License 2003 - 2024
MD State Medical License 2002 - 2003
Clinical Trials
- Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) Start of enrollment: 2010 Jul 01
- Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML) Start of enrollment: 2011 Nov 21
Publications & Presentations
PubMed
- Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eig...Yasmin Abaza, Eric S Winer, Guru Subramanian Guru Murthy, Rory M Shallis, Andrew H Matthews, Talha Badar, Emily M Geramita, Vamsi K Kota, Alok Swaroop, Peter Doukas, D...> ;American Journal of Hematology. 2024 Apr 1
- A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia.Mark J Levis, Alexander E Perl, Gary J Schiller, Amir T Fathi, Gail J Roboz, Eunice S Wang, Jessica K Altman, Trivikram Rajkhowa, Makoto Ando, Takeaki Suzuki, Ruth Ann...> ;Blood Advances. 2024 Mar 19
- Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients.Anthony D Sung, Thuy Koll, Shannon H Gier, Alessandro Racioppi, Griffin White, Meagan Lew, Marcia Free, Priyal Agarwal, Lauren M Bohannon, Ernaya J Johnson, Bharathi S...> ;Transplantation and Cellular Therapy. 2024 Apr 1
- Join now to see all
Journal Articles
- Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 InhibitorsAlexander Perl, MD, Clinical Cancer Research
- Phase 2b Study of Two Dosing Regimens of Quizartinib Monotherapy in FLT3-ITD Mutated, Relapsed or Refractory AMLAlexander E Perl, Mark J Levis, Stuart L Goldberg, Martin S Tallman, Hagop M Kantarjian, Gary J Schiller, Blood
Abstracts/Posters
- Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Quizartinib Vs Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) FLT3-ITD Acute ...Alexander E. Perl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Clinical Outcomes and Characteristics of Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)...Alexander E. Perl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)Clinically Relevant AbstractAlexander E. Perl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Treating Acute Myeloid Leukemia: Case Challenges and Emerging Therapies61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b StudyClinically Relevant Abstract61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Longitudinal Monitoring of AML Tumors with High-Throughput Single-Cell DNA Sequencing Reveals Rare Clones Prognostic for Disease Progression and Therapy Response2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
Gilteritinib Shows Efficacy in Patients with Acute Myeloid Leukemia with Prior Tyrosine Kinase Inhibitor TherapySeptember 10th, 2021- Novel Agents Hold Promise for Frontline AML TreatmentOctober 28th, 2020
Astellas Presents New Data on XOSPATA® (Gilteritinib) in FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia at the 2019 American Society of Hematology Annual MeetingDecember 2nd, 2019- Join now to see all
Hospital Affiliations
Hospital of the University of PennsylvaniaPhiladelphia, Pennsylvania
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
